A Single-arm Phase II Clinical Study of Camrelizumab Combined With Long-course Chemoradiotherapy for Total Neoadjuvant Therapy in Locally Advanced Low pMMR/MSS Rectal Cancer

ConditionLocally Advanced Rectal Cancer

Trial statusRecruiting

Trial phasePhase 2

Trial typeInterventional

Biological sexAll

Age18-75

SponsorChinese PLA General Hospital

About this trial

In pMMR/MSS locally advanced rectal cancer, can the innovative "chemo-immunotherapy induction + LCRT + chemo-immunotherapy consolidation" approach significantly improve the complete response rate and create opportunities for organ preservation?

Eligibility criteria

Qualifiers

Aged 18-75 years, male or female;

Disqualifiers

Prior or current receipt of any anti-tumor therapy for cancer, including surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, etc.

Trial design

Treatments tested in this trial

Camrelizumab

Treatment groups

44 Participants

are divided into 1 treatment group

Sponsors and collaborators

Chinese PLA General Hospital

Lead sponsor

Source ClinicalTrials.gov